Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Average (2021 - 2025)

Historic Equity Average for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.1 billion.

  • Krystal Biotech's Equity Average rose 2631.03% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2631.03%. This contributed to the annual value of $862.5 million for FY2024, which is 3260.5% up from last year.
  • As of Q3 2025, Krystal Biotech's Equity Average stood at $1.1 billion, which was up 2631.03% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Equity Average registered a high of $1.1 billion during Q3 2025, and its lowest value of $413.4 million during Q3 2021.
  • For the 5-year period, Krystal Biotech's Equity Average averaged around $697.1 million, with its median value being $637.9 million (2023).
  • In the last 5 years, Krystal Biotech's Equity Average crashed by 1141.14% in 2023 and then skyrocketed by 5594.86% in 2024.
  • Krystal Biotech's Equity Average (Quarter) stood at $500.9 million in 2021, then grew by 6.11% to $531.5 million in 2022, then surged by 44.36% to $767.3 million in 2023, then rose by 19.4% to $916.1 million in 2024, then grew by 18.9% to $1.1 billion in 2025.
  • Its Equity Average stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $965.5 million for Q1 2025.